Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407805 · ClinicalTrials.gov registry record
A Study to Learn About Sickle Cell Disease In Adult Patients
A clinical trial of Sickle Cell Disease, sponsored by Pfizer.
- Completed
- Registry status
- 98
- Enrollment target
- 5
- Study locations
NCT05407805: Completed study of Sickle Cell Disease, sponsored by Pfizer.
NCT05407805 is a study of Sickle Cell Disease that has completed, run by Pfizer. The registered enrollment target is 98 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05407805, a study of Sickle Cell Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment. SCD is a type of condition when there are fewer red blood cells to carry oxygen around the body. This disease can be passed on from parent to child and may cause pain, infections and damage to organs. This study is seeking participants who: * are confirmed with SCD * are on a stable regimen of disease changing treatment or have not received any disease changing treatment before the start of the study and do not plan any changes in their treatment during the 6-month study observation period For 6 months, participants will be asked to complete a daily electronic diary to report on their experience in the past 24 hours with sickle cell pain crisis (if they got any treatment and what medications they took), worst pain, worst tiredness, and their ability to perform usual physical activities. We will compare the experiences of people who are taking SCD-modifying therapy to those that are not taking a SCD-modifying therapy.
Primary Outcome
Physician-reported MU VOC: defined as an acute episode of pain with no other cause other than a VOC event that required a medical facility visit or contact with a health care professional and treatment with oral or parenteral narcotics, or non-steroidal anti-inflammatory drugs. Acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism (requiring a visit to a medical facility) were also considered MU VOC. Contact with healthcare professional included: called healthcare prov
Conditions Studied
Interventions
- OTHER Electronic Diary
Study Locations (5)
Maryland
- Mid-Atlantic Permanente Medical Group Largo Medical Center - Largo
- Mid-Atlantic Permanente Medical Group Largo Medical Center - Upper Marlboro
Florida
- Foundation for Sickle Cell Disease Research - Hollywood
Massachusetts
- Sanguine Biosciences, Inc. - Waltham
New York
- Cohen Children's Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2024-06-24 |
What the finished NCT05407805 record still lists
NCT05407805 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Electronic Diary is the first listed.
NCT05407805 lists 5 locations in 4 states (Maryland, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05407805 about?
NCT05407805 is a clinical study titled "A Study to Learn About Sickle Cell Disease In Adult Patients". The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment. SCD is a type of condition when there are fewer red blood cells to carry oxygen around ...
What is the current status of trial NCT05407805?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2022-02-10. Estimated completion is 2024-06-24.
What conditions does trial NCT05407805 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05407805?
The interventions under investigation include: Electronic Diary (OTHER).
Who is sponsoring clinical trial NCT05407805?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05407805 being conducted?
This trial has 5 study locations across Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05407805's enrollment target sits among peer trials
98 68th of 213 higher than 146 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI